ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
uniQure NV

uniQure NV (QURE)

14.79
-0.32
(-2.12%)
14.88
0.09
(0.61%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
14.88
Bid
14.81
Ask
14.88
Volume
1,969,101
14.40 Day's Range 15.13
3.73 52 Week Range 19.18
Market Cap
Previous Close
15.11
Open
15.01
Last Trade
1
@
14.85
Last Trade Time
Financial Volume
$ 29,352,634
VWAP
14.9066
Average Volume (3m)
1,844,124
Shares Outstanding
54,748,496
Dividend Yield
-
PE Ratio
-3.38
Earnings Per Share (EPS)
-4.38
Revenue
35.05M
Net Profit
-239.56M

About uniQure NV

uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipel... uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Amsterdam, North Holland, Nld
Founded
-
uniQure NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker QURE. The last closing price for uniQure NV was $15.11. Over the last year, uniQure NV shares have traded in a share price range of $ 3.73 to $ 19.18.

uniQure NV currently has 54,748,496 shares outstanding. The market capitalization of uniQure NV is $827.25 million. uniQure NV has a price to earnings ratio (PE ratio) of -3.38.

QURE Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.04-12.056737588716.9217.614.7789793715.83784397CS
40.171.1556764106114.7117.613.8119421115.58571143CS
120.10.67658998646814.7817.67.76184412412.86452242CS
26-1.98-11.74377224216.8619.187.76143878913.55103113CS
529.99204.2944785284.8919.183.73191407811.12870467CS
1561.168.4548104956313.7228.2553.73120562111.71551266CS
260-50.92-77.386018237165.871.453.7393002116.26808549CS

QURE - Frequently Asked Questions (FAQ)

What is the current uniQure NV share price?
The current share price of uniQure NV is $ 14.88
How many uniQure NV shares are in issue?
uniQure NV has 54,748,496 shares in issue
What is the market cap of uniQure NV?
The market capitalisation of uniQure NV is USD 827.25M
What is the 1 year trading range for uniQure NV share price?
uniQure NV has traded in the range of $ 3.73 to $ 19.18 during the past year
What is the PE ratio of uniQure NV?
The price to earnings ratio of uniQure NV is -3.38
What is the cash to sales ratio of uniQure NV?
The cash to sales ratio of uniQure NV is 23.07
What is the reporting currency for uniQure NV?
uniQure NV reports financial results in USD
What is the latest annual turnover for uniQure NV?
The latest annual turnover of uniQure NV is USD 35.05M
What is the latest annual profit for uniQure NV?
The latest annual profit of uniQure NV is USD -239.56M
What is the registered address of uniQure NV?
The registered address for uniQure NV is PAASHEUVELWEG 25A, AMSTERDAM, NORTH HOLLAND, 1105 BP
What is the uniQure NV website address?
The website address for uniQure NV is www.uniqure.com
Which industry sector does uniQure NV operate in?
uniQure NV operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CEROCERo Therapeutics Holdings Inc
$ 19.92
(190.04%)
57.35M
ACXPAcurx Pharmaceuticals Inc
$ 0.8149
(165.35%)
337.45M
EYENEyenovia Inc
$ 6.96
(134.34%)
29.94M
RBNERobin Energy Ltd
$ 10.60
(92.03%)
45.44M
RELIReliance Global Group Inc
$ 2.20
(86.44%)
19.29M
SDSTStardust Power Inc
$ 0.186
(-52.10%)
39.42M
SHOTWSafety Shot Inc
$ 0.0161
(-45.97%)
12.35k
RUNSunrun Inc
$ 5.78
(-40.04%)
120.05M
SEDGSolarEdge Technologies Inc
$ 15.94
(-33.53%)
33.14M
GOVXGeoVax Labs Inc
$ 0.8924
(-32.39%)
2.64M
PCSAProcessa Pharmaceuticals Inc
$ 0.2632
(16.93%)
575.5M
GNLNGreenlane Holdings Inc
$ 0.0104
(-16.13%)
392.94M
HCTIHealthcare Triangle Inc
$ 0.022
(-16.67%)
356.57M
ACXPAcurx Pharmaceuticals Inc
$ 0.8149
(165.35%)
337.45M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 11.9373
(-7.75%)
143.55M

QURE Discussion

View Posts
PonkenPlonken PonkenPlonken 6 months ago
dont like throwing the term around but this has buyout written all over
super strong up here

Novartis for AMT-130 Huntington program?
👍️0
tw0122 tw0122 6 months ago
$15.72 + 113% time to exit all hard time breaking $15.78 resistance which would have led to $17s
👍️0
tw0122 tw0122 6 months ago
$15.35 + 103%
👍️0
PonkenPlonken PonkenPlonken 6 months ago
rock n roll
👍️0
tw0122 tw0122 6 months ago
$13.71 + 88%
👍️0
PonkenPlonken PonkenPlonken 6 months ago
Never before data and 11$ in cash held back by ex stock broker CEO Matt Kapusta. Is too busy milking shareholders vs advancing trials.
but dont worry, he wont make it go kaput.
👍️0
PonkenPlonken PonkenPlonken 6 months ago
Never before data and 11$ in cash held back by ex stock broker CEO Matt Kapusta. Is too busy milking shareholders vs advancing trials.
but dont worry, he wont make it go kaput.
👍️0
PonkenPlonken PonkenPlonken 8 months ago
turnaround in the making
👍️0
PonkenPlonken PonkenPlonken 8 months ago
Here it comes
Still 11$ in cash and super science. Held back by blood leech Ex-Wallstreet CEO... BP wont care
👍️0
Biggiee Biggiee 8 months ago
Get in or don’t. It’s time
$QURE
👍️0
PonkenPlonken PonkenPlonken 9 months ago
Everyone forgot about this as they are much to busy chasing the next ultra risky 10% flip.
SOOO undervalued. Suppressed by bored traders and gamblers leaving.
The data will speak again and people will realize this is worth 2-4bn.
👍️0
tbonaces80 tbonaces80 11 months ago
Buying for swing. Tier 1
👍️0
retireat40 retireat40 11 months ago
Agree until more news is released.
👍️0
Romiman Romiman 11 months ago
Got in at 5.85, I’ll be out tomorrow, this one is done.
👍️0
retireat40 retireat40 11 months ago
WTH? New LOD every time I check.
👍️0
retireat40 retireat40 11 months ago
Nope
👍️0
retireat40 retireat40 11 months ago
Turd city…
👍️0
retireat40 retireat40 11 months ago
Even less volume today than last Friday.
👍️0
retireat40 retireat40 11 months ago
Agree. Odd that it trades in the 8’s
👍️0
PonkenPlonken PonkenPlonken 11 months ago
I became an investor the second i saw the results but i also traded around my position. Ergo I am riding a free ticket now.
Company has 11$ per share in cash and the science is probably worth 2-4bn $.
👍️0
retireat40 retireat40 11 months ago
Bull or bear?
👍️0
retireat40 retireat40 11 months ago
Looked like crapola today
👍️0
tbonaces80 tbonaces80 11 months ago
Flagg forming
👍️0
PonkenPlonken PonkenPlonken 11 months ago
institutions use liquidity = take a seat and watch the scenario unfold.
👍️0
retireat40 retireat40 11 months ago
We’ll see. 80% drop in volume today.
👍️0
TechandBio TechandBio 11 months ago
UniQure Interesting move here solid pipeline added a few calls for early July for fun.
Keep an eye o Ice Cure killing cancer by cryoblation ICCM one of the most undervalued stocks.
$QURE
👍️0
tbonaces80 tbonaces80 11 months ago
Great chart. Shooting for a rip beteen $12.41-$16.75.
👍️0
PonkenPlonken PonkenPlonken 11 months ago
traders are too busy trying to make $ in silly names. Every few months there is a play like this.... that doesnt require much thinking-- only spotting it and letting the big guys do the lifting.
👍️0
PonkenPlonken PonkenPlonken 11 months ago
Listen to Victor Sung on the recent call. You dont need to be in the know to hear he hasnt seen anything similar

https://edge.media-server.com/mmc/p/m4opdukf
👍️0
Monksdream Monksdream 1 year ago
QURE under $5
👍️0
Liam859 Liam859 1 year ago
$QURE $5.14 buy it up
👍️0
MiamiGent MiamiGent 3 years ago
QURE

$26.36 +3.36 (+14.61%)
As of Nov-23-20224:00:00 PM ET

https://stockcharts.com/h-sc/ui?s=QURE

FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
BENZINGA 8:12 AM ET Nov-23-2022

UniQure N.V.'s (NASDAQ:QURE) partner CSL Limited (OTC:CSLLY) has received FDA approval for Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B.
CSL licensed the exclusive global rights to Hemgenix from uniQure in May 2021.
UniQure has received about $500 million so far from CSL and will also be eligible to get up to an additional $1.5 billion in commercial milestone payments and royalties.
Cowen analyst Joseph Thome said that Hemgenix's price of $3.5 million is higher than the brokerage's estimated $1.9 million, but its consultants have been optimistic about the therapy's uptake, Reuters reported.
Results from the pivotal HOPE-B trial support the FDA approval, the largest gene therapy trial in hemophilia B.
Results from the study demonstrated that Hemgenix allowed patients to produce mean factor IX activity of 39% at six months and 36.7% at 24 months post-infusion.
Seven to 18 months post-infusion, the mean adjusted annualized bleeding rate (ABR) for all bleeds was reduced by 54% compared to the six-month lead-in period on factor IX prophylactic replacement therapy (4.1 to 1.9).
In addition, 94% of patients treated with Hemgenix discontinued prophylaxis and remained free of previous continuous routine prophylaxis therapy.
The FDA has already cleared two gene therapies, Zynteglo and Skysona, from Bluebird bio Inc (NASDAQ: BLUE) in August and September, respectively.
👍️0
Glider549 Glider549 3 years ago
Whoops!
👍️0
ralphey ralphey 3 years ago
Insiders selling big time while biopharmcatalyst site tries to pump - noit a good sign
👍️0
Sunnycupid Sunnycupid 8 years ago
Profit taking time .. Good time to short this .. I want to be in for a short
👍️0
Thoro Thoro 8 years ago
QURE $9.15 high today, nice.
👍️0
Thoro Thoro 8 years ago
This thing is pretty volatile lately.
👍️0
Thoro Thoro 8 years ago
QURE Looked great hitting $9.00 today
👍️0
Thoro Thoro 8 years ago
QURE General Information

http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=QURE.O
👍️0
Thoro Thoro 8 years ago
Uniqure NV (QURE) Money Flow Index Nearing Key Level

http://tuckermantimes.com/uniqure-nv-qure-money-flow-index-nearing-key-level/247578/

👍️0
Thoro Thoro 8 years ago
Erratic Trading Showing Unusual Volume in Shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) and uniQure N.V. (NASDAQ:QURE)

https://www.concordregister.com/erratic-trading-showing-unusual-volume-in-shares-of-concert-pharmaceuticals-inc-nasdaqcnce-and-uniqure-n-v-nasdaqqure/

👍️0
Thoro Thoro 8 years ago
uniQure N.V. NASDAQ:QURE Sees High Volatility in Session

https://aikenadvocate.com/uniqure-n-v-nasdaqqure-sees-high-volatility-in-session/290264/
👍️0
Thoro Thoro 8 years ago
uniQure N.V. (QURE) PT Set at $13.00 by Chardan Capital

https://weekherald.com/2017/07/24/uniqure-n-v-qure-pt-set-at-13-00-by-chardan-capital.html
👍️0
Rogerthat1 Rogerthat1 8 years ago
This dog has always been a turd. Why did it run last couple days? Already see signs of rollover on today's intraday imo. $QURE
👍️0
Dutchdaan Dutchdaan 8 years ago
buying here
👍️0
Panzer Panzer 8 years ago
Lost all patience in this pos
👍️0
redsox17 redsox17 9 years ago
Patient is a virtue.
If you know what you are doing it pays off.
👍️0
jaytea jaytea 9 years ago
That's why it's down another 3%
👍️0
redsox17 redsox17 9 years ago
Trust me they are. They just don't want you to think that way.
👍️0
jaytea jaytea 9 years ago
The market does not seem to be overly impressed.
👍️0

Your Recent History

Delayed Upgrade Clock